Mentari Therapeutics (formerly InMed Pharmaceuticals) completed a one-for-ten reverse stock split effective November 4, 2026, reducing outstanding shares from approximately 5.5 million to roughly 549,374. The company also legally changed its name and redomiciled from British Columbia to Nevada. Shareholders approved key merger proposals, including the issuance of Nasdaq-required shares for a pending acquisition by Mentari Therapeutics, Inc., and adopted new equity incentive plans. Trading on Nasdaq under symbol INM resumes November 5 on a post-consolidation basis with one contingent value right issued per share. The company is a pharmaceutical firm developing small molecule drug candidates.
